activities Net cash used in financing activities Net cash used in investing activities Ending cash and cash equivalents (31 Mar 2019) Unit: THB millions Osotspa Public Company Limited Q1’19 Management

: Baht millions) For the year ended 31 st March Consolidated financial statement Apr 2018 - Mar 2019 Apr 2017 - Mar 2018 Change % Change Revenue from sales & service 3,293.90 3,376.19 -82.29 -2.4% Other

% of paid up capital, Total investment 50 Millions baht. The acquisition of BS Myco Biotech shares will result in the BS Myco Biotech being a subsidiary of the Company. The Company signed the share

million baht. 6. Source of fund for asset acquired. The company‟s cash flow and/or Promissory Note amount 40 millions. 7. Criteria to determine the Value of Consideration. The company has decided to hire

: Baht millions) For the year ended 31 st March Consolidated financial statement Apr 2017 - Mar 2018 Apr 2016 - Mar 2017 Change % Change Revenue from sales & service 3,376.19 3,199.82 176.37 5.5% Other

its subsidiaries as details below: (Unit: Baht millions) For the period of three months Consolidated financial statement ended 30th June Apr 2018 - June 2018 Apr 2017 - June 2017 Change % Change Revenue

financial advisor using Discounted Cash Flow Approach method. By purchase price between Baht 46.38-94.77 millions. The Board of Directors is of the opinion that the price not over Baht 60 Millions. The

% y-on-y primarily due to 1) net negative impacts of Baht 111 millions from external factors [consisting of 1.1) Baht 71 million from a 9.4% y-on-y increase of gas cost per unit but a 0.9% increase in

ended 31st December 2018 of the Company and its subsidiaries as details below: (Unit: Baht millions) 1. Operating Performance For the period of three months ended 31st Dec 2018, the net profits for the

period of 1st half ended 30th September 2017 of the Company and its subsidiaries as details below: (Unit: Baht millions) 1. Operating Performance For the period of three months ended 30th Sept 2017, the